BOSTON, MA — November 12, 2025 — Glytec, the pioneer and leading provider of AI-powered diabetes and glycemic management for hospitals and health systems, today announced the publication of a KLAS First Look report. In this report, KLAS evaluated Glytec’s flagship solution, Glucommander®, an EHR-integrated insulin management platform designed to reduce glycemic events and simplify insulin dosing across inpatient settings.
“We’re honored that KLAS has spotlighted our customers’ success in improving patient safety and standardizing glycemic care,” said Patrick Cua, CEO of Glytec. “This recognition reinforces our commitment to empowering hospitals with evidence-based insulin management technology that delivers measurable outcomes for patients and providers alike.”
The First Look report also noted that Glucommander’s EHR integration—validated across Epic, Oracle Health, Altera Digital Health, and MEDITECH—streamlines nursing workflows, enhances documentation accuracy, and supports both IV and SubQ insulin regimens. Customers cited ease of use, clinical outcomes, and responsive vendor support as key strengths.
Healthcare leaders and media can access the full KLAS First Look report at this link.
*Based on limited data
About Glytec
Glytec’s industry-leading, AI-driven technology platform, trusted by over 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay and readmissions, and optimizing clinical workflows. Its flagship solution, Glucommander®—the first-ever FDA-cleared cloud-based insulin management software—integrates seamlessly with EHRs, providing advanced clinical decision support, workflow alerts, patient monitoring, and comprehensive analytics. Supported by industry awards and over 100 patents and 100 peer-reviewed publications, Glytec is dedicated to improving care from the hospital to the home for consumers, providers, and payors. For more information, visit www.glytec.com or follow Glytec on LinkedIn.
Media Contact:
Glytec Public Relations
GlytecPR@glytec.com
